Galena Biopharma (GALE) Receives ‘Analyst’ Rating

Galena Biopharma (GALE) : Zacks Investment Research ranks Galena Biopharma (GALE) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2, which indicates as a Buy.


Also, Equity Analysts at the Raymond James downgrades the rating on Galena Biopharma (NASDAQ:GALE). The brokerage firm has issued a Market Perform rating on the shares. The shares were previously rated Outperform. The rating by the firm was issued on June 29, 2016.

Galena Biopharma (NASDAQ:GALE): After opening at $0.3288, the stock dipped to an intraday low of $0.3149 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.3419 and the buying power remained strong till the end. The stock closed at $0.3327 for the day, a gain of 0.76% for the day session. The total traded volume was 4,225,001. The stocks close on the previous trading day was $0.3302.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.